Browse EX-10 agreements

Exhibit 10.2

 

MADRIGAL PHARMACEUTICALS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN

 

The purpose of the Madrigal Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Madrigal Pharmaceuticals, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of Stock (as defined in Section 11). An aggregate of 460,840 shares of Stock have been approved and reserved for this purpose.

…

Exhibit 10.3

 

MADRIGAL PHARMACEUTICALS, INC.

 

NONQUALIFIED DEFERRED COMPENSATION PROGRAM

Effective August 1, 2026

 

ARTICLE 1

DESIGNATION OF PLAN AND DEFINITIONS

 

Section 1.1. Title and Purpose.

 

This Plan shall be known as the “Madrigal Pharmaceuticals, Inc. Nonqualified Deferred Compensation Program.” The purpose of this Plan is to provide specified benefits to a select group of management or highly compensated employees, or non-employee members of the Board of Directors, who contribute materially to the continued growth, development and future business success of Madrigal Pharmaceuticals, Inc. (“Madrigal”) and its Subsidiaries, if any, that sponsor this Plan. This Plan shall be unfunded for tax purposes and for purposes of Title I of ERISA.

 

The Plan is intended to comply with all applicable laws, including Code Section 409A and will be administered, operated and construed in accordance with this intention.

 

Section 1.2. Definitions.

…

Exhibit 10.1

 

MADRIGAL PHARMACEUTICALS, INC.

 

2026 STOCK PLAN

 

SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

 

The name of the plan is the Madrigal Pharmaceuticals 2026 Stock Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and its Subsidiaries and Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

 

The following terms shall be defined as set forth below:

…

IMAGENEBIO, INC.

AMENDED AND RESTATED

2025 EQUITY INCENTIVE PLAN

ADOPTED BY THE BOARD OF DIRECTORS: DECEMBER 12, 2024

APPROVED BY THE STOCKHOLDERS: JULY 15, 2025

AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: APRIL 27, 2026

APPROVED BY THE STOCKHOLDERS: JUNE 16, 2026

1. GENERAL.

(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan.

…

APYX MEDICAL CORPORATION

5115 Ulmerton Road

Clearwater, Florida 33760

June 11, 2026

 

Stavros Vizirgianakis

C/O Apyx Medical Corporation

5115 Ulmerton Road

Clearwater, Florida 33760

 

Re: Appointment as Executive Chairman

 

Dear Stavros:

 

This letter agreement (this “Agreement”) confirms the terms of your appointment as Executive Chairman of Apyx Medical Corporation, a Delaware corporation (the “Company”), and the grant to you of restricted stock units (“RSUs”), under the Company’s 2023 Share Incentive Plan (the “Plan”). This Agreement, including the granting of the RSU Award (defined below), is being entered into and provided in recognition of your service to the Company and your expected continued contributions in the role of Executive Chairman.

 

…

CREDIT AGREEMENT

 

Dated as of June 11, 2026

 

among

 

ISQ OPEN INFRASTRUCTURE COMPANY LLC – SERIES II, as the Initial Primary Borrower,

 

and

 

The other Borrowers from time to time party hereto, as Borrowers,

 

The Lenders from time to time party hereto,

 

and

 

SUMITOMO MITSUI BANKING CORPORATION, as Administrative Agent and Lead Arranger

 

 

 

 

 

Table of Contents

 

ARTICLE I DEFINITIONS AND ACCOUNTING TERMS

1

 

1.01

Defined Terms

1

 

1.02

Other Interpretive Provisions.

47

 

1.03

Accounting Terms.

48

 

1.04

Rounding.

49

 

1.05

[Reserved].

49

 

1.06

[Reserved].

49

 

1.07

[Reserved].

49

 

1.08

Times of Day.

49

 

1.09

[Reserved].

49

 

1.10

Rates.

49

 

1.11

Divisions.

50

ARTICLE II THE COMMITMENTS AND COMMITTED BORROWINGS

50

 

2.01

Loans.

50

 

2.02

Borrowings, Conversions and Continuations of Loans.

51

 

2.03

[Reserved].

52

 

2.04

Joint and Several Liability.

52

 

2.05

Prepayments; Cash Sweep Events.

53

 

2.06

Termination or Reduction of Commitments.

55

 

2.07

…

SECOND AMENDMENT

TO THE

INSIGHT MOLECULAR DIAGNOSTICS INC.

AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN

 

This SECOND AMENDMENT TO THE INSIGHT MOLECULAR DIAGNOSTICS INC. AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (this “Amendment”), effective as of June 11, 2026, is made and entered into by Insight Molecular Diagnostics Inc., a California corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan (as amended, the “Plan”).

 

RECITALS

 

WHEREAS, Section 13.1 of the Plan provides that the Board of Directors of the Company (the “Board”) may amend the Plan at any time and from time to time;

…

Exhibit 10.1

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

HCA Management Services, L.P.

Refresh Amendment

Vendor: Outset Medical, Inc.

Agreement No. [***]

Agreement Effective Date: May 1, 2020

Refresh Amendment Effective Date: June 15, 2026

 

As of the Refresh Amendment Effective Date above (“Refresh Amendment”), HCA Management Services, L.P., a Delaware limited partnership, having its principal place of business at 1100 Dr. Martin L. King, Jr. Blvd., Suite 1100, Nashville, TN 37203 (“HMS”), and Outset Medical, Inc. a Delaware Corporation, with a place of business at 3052 Orchard Drive, San Jose, CA 95134 (“Vendor”), agree as follows:

 

WHEREAS, HMS and Vendor are parties to the Purchasing Agreement dated May 1, 2020, for Tablo Hemodialysis, as amended, (“Agreement”);

…

Document

OMNIBUS AMENDMENT NO. 2

This OMNIBUS AMENDMENT NO. 2 (this “Amendment”), dated as of June 16, 2026, is by and among (1) WORKHORSE GROUP INC., a Nevada corporation (“Borrower”), (2) the Guarantors (as defined below) party hereto and (3) MOTIVE GM HOLDINGS II LLC (“Lender”). Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreements (as defined below), as applicable.

WITNESSETH

…

ex101-votingandsupportag

Execution Version 1 Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of June 15, 2026 (the “Effective Date”), is entered into by and among SP Evolution HoldCo II, LLC, a Delaware limited liability company (“Parent”), SP Evolution BidCo II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“Merger Sub”), and the undersigned shareholders (each, a “Shareholder” and collectively, the “Shareholders”) of Simulations Plus, Inc., a California corporation (the “Company”). Capitalized terms used but not defined herein shall have the meanings given to them in the Merger Agreement (as defined below). RECITALS WHEREAS, concurrently with the execution and delivery of this Agreement, the Company, Parent and Merger Sub have entered into an Agreement and Plan of Merger (as may be amended from time to time, the “Merger Agreement”), which provides for the merger of Merger Sub with and into the Company (the “Merger”) with the Company surviving the Merger as a wholly-owned subsidiary of Pare

…

KAIXIN HOLDINGS 2026 EQUITY INCENTIVE PLAN

 

The Kaixin Holdings 2026 Equity Incentive Plan (the “Plan”) was adopted by the Board of Kaixin Holdings, an exempted company with limited liability incorporated in the Cayman Islands (together with its successors and assigns, the “Company”) under the applicable laws and regulations of that jurisdiction.

 

Article 1 PURPOSE

 

The purpose of the Plan is to foster and promote the long-term financial success of the Company and its Subsidiaries and materially increase the value of the Company and its Subsidiaries by (a) encouraging the long-term commitment of the Employees, Consultants, and Outside Directors; (b) motivating performance of the Employees, Consultants, and Outside Directors by means of long-term performance related incentives; (c) encouraging and providing Employees, Consultants, and Outside Directors with an opportunity to obtain an ownership interest in the Company; (d) attracting and retaining outstanding Employees, Consultants, and Outside Directors by providing incentive compensation opportunities;

…

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) dated as of June 15, 2026 by and among (the “Execution Date”), by and between Greenland Mines Ltd a Delaware corporation (the “Company”) and Purchaser identified on the signature pages hereto (the “Purchaser”).

 

W I T N E S S E T H:

 

WHEREAS, pursuant to Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 promulgated under Regulation D (“Regulation D”) thereunder in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “Commission”), the Company is conducting a private offering (the “Offering”) of shares (a “Share”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”);

 

WHEREAS, Purchaser desires to purchase that number of Shares set forth on Purchaser’s signature page attached hereto on the terms and conditions hereinafter set forth.

…